2019-2021 Drug Discovery for Neurodegeneration Conferences

2019-2021 神经退行性疾病药物发现会议

• 批准号: 10180809
• 负责人: Howard M. Fillit
• 金额: $ 7.49万
• 依托单位: ALZHEIMER'S DRUG DISCOVERY FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-01-15 至 2022-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10180809
• 关键词: Academia; Address; Advanced Development; Advisory Committees; Aging; Alzheimer' s Disease; Area; Basic Science; Biologic Development; Case Study; Clinical Trials; Collaborations; Communities; Development; Discipline; Disease; District of Columbia; Drug Industry; Evaluation; Fostering; Foundations; Funding; Goals; Grant; Industry; Infrastructure; Innovative Therapy; International; Knowledge; Lead; Learning; Mentors; Minority; Multiple Sclerosis; NIH Program Announcements; Nerve Degeneration; Neurodegenerative Disorders; Parkinson Disease; Participant; Prevention; Process; Research; Research Contracts; Research Personnel; Resource Sharing; Resources; Schedule; Science; Scientist; Surveys; Testing; Training; Translating; Translational Research; U-Series Cooperative Agreements; United States National Institutes of Health; Update; Woman; acronyms; career; clinical candidate; drug development; drug discovery; education resources; effective therapy; graduate student; meetings; multidisciplinary; nervous system disorder; new therapeutic target; next generation; novel; novel therapeutics; outreach; posters; pre-clinical research; prevent; programs; public-private partnership; quantum; skills; small molecule; symposium; therapy development; trend; web portal; web site

PROJECT SUMMARY/ABSTRACT There is a well-documented knowledge and resource gap in translating basic research into novel therapeutics. Outside of the pharmaceutical industry, there are very few opportunities for the next generation of scientific leaders to learn about the drug discovery and development process in general, and particularly for neurodegenerative diseases. To meet this need, the Alzheimer’s Drug Discovery Foundation (ADDF) developed the annual Drug Discovery for Neurodegeneration (DDND) conference, which has reached 1,698 participants since its inception in 2007. The ADDF requests a U13 Cooperative Agreement conference grant for three years of support for its DDND conference, scheduled for the Southern CA area in March 2019; Miami, FL or Washington DC in March 2020; and the Southern CA area in March 2021. The goals of these didactic conferences are consistent with the initiatives set forth at the NIH’s 2012 and 2015 Alzheimer’s Disease Research Summits: to bridge the knowledge gap in drug discovery for neurodegenerative diseases; to bring together interdisciplinary scientists to stimulate new ways of combining skills and disciplines; and to provide networking opportunities for these scientists to exchange ideas and resources. These conferences will provide participants with fundamental knowledge and resources on developing new drugs to treat and prevent neurodegenerative diseases, and will address the challenges associated with the following sub-topics: Embarking on a Drug Discovery Campaign; Drug Discovery: From Lead to Clinical Candidate; Accelerating Therapies into Clinical Trials; Strategies for CNS Targets: Case Study Examples; and Building the Infrastructure to Commercialize Science into Products. Discussions will include relevant examples focused on small molecule and biologic development for neurodegenerative diseases. Sessions will consist of 20-minute presentations with 10-minute Q&As, and the program will include sessions for networking, mentoring, poster sessions presented by young investigators, and an early investigator career panel. With respect to public-private partnerships, the ADDF will invite 21 internationally recognized scientists from academia, industry, and the NIH to serve as chairs or speakers. We have assembled a Scientific Advisory Committee that has agreed to participate for the next three years to assist in the development of the conferences. It is anticipated that these conferences will serve 150 scientists annually from diverse backgrounds, including women, minorities, young/junior investigators, and graduate students.

项目摘要/摘要 将基础研究转化为新颖的知识和资源差距有据可查 疗法。在制药行业之外，很少有机会 下一代科学领导者了解药物发现和开发过程 通常，尤其是对于神经退行性疾病。为了满足这种需求，阿尔茨海默氏症 药物发现基金会（ADDF）开发了年度药物发现 神经变性（DDND）会议，该会议已达到1,698名参与者。 2007年的成立。ADDF要求为三个 多年支持其DDND会议，计划于2019年3月在南加利福尼亚州地区举行； 佛罗里达州迈阿密或华盛顿特区2020年3月；以及2021年3月的南部加利福尼亚地区。 这些教学会议的目标与NIH的倡议一致 2012年和2015年阿尔茨海默氏病研究峰会：弥合毒品知识差距 神经退行性疾病的发现；将跨学科科学家汇集在一起 刺激结合技能和学科的新方法；并提供网络机会 这些科学家交换思想和资源。 这些会议将为参与者提供基本知识和资源 开发新药来治疗和预防神经退行性疾病，并将解决 与以下子主题相关的挑战：启动毒品发现 活动;药物发现：从导致临床候选人；加速疗法 临床试验；中枢神经系统目标的策略：案例研究实例；并建造 将科学商业化为产品的基础设施。讨论将包括相关 旨在针对神经退行性疾病的小分子和生物学发育的例子。 会议将由10分钟的问答组成20分钟的演讲，该计划将 包括与年轻调查员举行的网络，心理和海报会议的会议， 还有一个早期的调查员职业小组。 关于公私伙伴关系，ADDF将邀请21种国际认可 来自学术界，工业和NIH的科学家担任主席或演讲者。我们有 组建了一个科学咨询委员会，该委员会同意参加接下来的三个 多年来协助会议的发展。预计这些会议将会 每年在包括妇女，少数族裔， 年轻/初级调查人员和研究生。